Skip to main content

Pseudomonas Aeruginosa

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Sandoz
SandozAustria - Kundl
1 program
1
Tobramycin inhalation powderPhase 31 trial
Active Trials
NCT00982930Completed55Est. Oct 2011

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozTobramycin inhalation powder

Clinical Trials (1)

Total enrollment: 55 patients across 1 trials

NCT00982930SandozTobramycin inhalation powder

Open Label Extension to Bridging Study CTBM100C2303

Start: Aug 2009Est. completion: Oct 201155 patients
Phase 3Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.